NuVasive Inc. (NASDAQ:NUVA) shares hit a new 52-week high on Monday . The stock traded as high as $63.41 and last traded at $63.35, with a volume of 264,316 shares. The stock had previously closed at $62.20.

Several research analysts have weighed in on NUVA shares. Jefferies Group upped their target price on NuVasive from $63.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, July 27th. JPMorgan Chase & Co. upgraded NuVasive from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $55.00 to $74.00 in a research note on Wednesday, July 13th. TheStreet downgraded NuVasive from a “buy” rating to a “hold” rating in a research note on Wednesday, April 27th. Needham & Company LLC reiterated a “hold” rating on shares of NuVasive in a research note on Wednesday, April 27th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of NuVasive in a research note on Wednesday, April 27th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $64.38.

The company has a 50 day moving average price of $59.96 and a 200 day moving average price of $51.33. The stock has a market capitalization of $3.18 billion and a P/E ratio of 65.63.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Tuesday, July 26th. The medical device company reported $0.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.04. The firm earned $236.50 million during the quarter, compared to analyst estimates of $232.86 million. During the same period in the prior year, the business earned $0.31 EPS. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. Analysts expect that NuVasive Inc. will post $1.65 earnings per share for the current fiscal year.

In other NuVasive news, EVP Jason Hannon sold 2,920 shares of NuVasive stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $62.80, for a total value of $183,376.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Other hedge funds recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in NuVasive by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,030,568 shares of the medical device company’s stock worth $55,765,000 after buying an additional 32,254 shares in the last quarter. Jennison Associates LLC increased its stake in NuVasive by 41.5% in the fourth quarter. Jennison Associates LLC now owns 412,893 shares of the medical device company’s stock worth $22,342,000 after buying an additional 121,061 shares in the last quarter. Principal Financial Group Inc. increased its stake in NuVasive by 4.8% in the fourth quarter. Principal Financial Group Inc. now owns 330,134 shares of the medical device company’s stock worth $17,863,000 after buying an additional 15,216 shares in the last quarter. New York State Common Retirement Fund increased its stake in NuVasive by 44.3% in the fourth quarter. New York State Common Retirement Fund now owns 203,394 shares of the medical device company’s stock worth $11,006,000 after buying an additional 62,437 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in NuVasive by 1.9% in the fourth quarter. California Public Employees Retirement System now owns 132,000 shares of the medical device company’s stock worth $7,143,000 after buying an additional 2,400 shares in the last quarter.

Nuvasive, Inc is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.